Open Payments

CHILDRENS MERCY HOSPITAL

Type
Teaching hospital
Where
Kansas City, MO
Medicare CCN
263302
Received
$3,216,241 in 551 records, 2021 ($202,311 general, $3,013,929 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2021General payment19$202,311
2021Research payment532$3,013,929

By company

CompanyRecordsAmountYears
PFIZER INC.31$506,9422021
BioFire Diagnostics, LLC65$487,3422021
Merck Sharp & Dohme LLC9$383,5592021
Organon Llc7$377,1242021
Edwards Lifesciences Corporation65$204,3902021
VERTEX PHARMACEUTICALS INCORPORATED11$199,9752021
JAZZ PHARMACEUTICALS INC.5$144,3642021
Eli Lilly and Company12$139,3022021
Amgen Inc.10$129,0712021
Luminex Corporation6$112,0772021
Alexion Pharmaceuticals, Inc.51$82,2092021
Dexcom, Inc.10$63,8862021
Novartis Pharmaceuticals Corporation3$36,8262021
Regeneron Pharmaceuticals, Inc.3$36,4002021
GENZYME CORPORATION2$29,5642021
Travere Therapeutics, Inc.42$24,7852021
ABBVIE INC.9$23,0932021
Boehringer Ingelheim Pharmaceuticals, Inc.4$22,5602021
Teva Pharmaceuticals USA, Inc.4$22,1202021
Genentech, Inc.9$21,6822021
GLOBAL BLOOD THERAPEUTICS, INC.9$17,3382021
SANOFI PASTEUR INC.4$17,0292021
Allergan, Inc.6$14,9002021
New York Blood Center, Inc.1$13,3602021
Rockwell Medical, Inc.2$12,7502021
Bio-Rad Laboratories, Inc.3$11,9442021
Gilead Sciences, Inc.14$11,4732021
Astellas US Technologies26$8,4462021
E.R. Squibb & Sons, L.L.C.4$7,5772021
Astellas Pharma Global Development1$7,5642021
Boehringer Ingelheim Pharma GmbH & Co.KG4$7,1162021
SANOFI US SERVICES INC.5$5,5802021
Takeda Pharmaceuticals U.S.A., Inc.1$4,9942021
Novo Nordisk AS38$4,1532021
Aimmune Therapeutics, Inc.18$3,3402021
AstraZeneca UK Limited2$2,8072021
Boehringer Ingelheim France S.A.S.3$2,6012021
United Therapeutics Corporation2$2,4502021
Cumberland Pharmaceuticals, Inc.1$1,9002021
DiaSorin Molecular LLC1$1,5002021
PENTAX of America, Inc.1$1,3372021
Linvatec Corporation2$1,3282021
Incyte Corporation14$1,2922021
Boehringer Ingelheim Italia S.p.A.21$1,2172021
Abbott Laboratories2$1,0822021
AMAG Pharmaceuticals, Inc.1$1,0002021
Catalent Pharma Solutions, LLC1$1,0002021
GE HEALTHCARE1$6992021
Mylan Specialty L.P.2$6122021
Streck LLC1$3302021

By nature of payment

NatureRecordsAmount
Research payment532$3,013,929
Compensation for services other than consulting, including serving as faculty or as a speaker at a v9$113,210
Grant1$60,000
Honoraria1$24,497
Long term medical supply or device loan3$2,666
Charitable Contribution2$1,050
Education1$699
Food and Beverage1$184
Debt forgiveness1$5

Records

DateCompanyAmountNatureFormProductStudyYear
2021-12-31Merck Sharp & Dohme LLC$30,942Research paymentIn-kind items and services Biological, VACCINEA Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerabilit2021
2021-12-31Edwards Lifesciences Corporation$5,200Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2021
2021-12-31Boehringer Ingelheim Pharma GmbH & Co.KG$1,524Research paymentIn-kind items and servicesTRADJENTA Drug, DIABETES52 wks Eff. & Saf. Ph III in Paediatrics2021
2021-12-31PENTAX of America, Inc.$1,337Long term medical supply or device loanIn-kind items and servicesVIDEO BRONCHOSCOPE Device, Gastroenterology2021
2021-12-31Linvatec Corporation$1,261Long term medical supply or device loanIn-kind items and servicesAIRSEAL Device, GENERAL SURGERY2021
2021-12-31Edwards Lifesciences Corporation$885Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2021
2021-12-31AstraZeneca UK Limited$124Research paymentIn-kind items and servicesBYDUREON Drug, Cardiovascular and MetabolismA Phase 3 Double Blind Placebo Controlled Randomized Multi Center Study To Assess the Safety and Efficacy of Exenatide O2021
2021-12-31Aimmune Therapeutics, Inc.$21Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-12-29PFIZER INC.$7,450Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2021
2021-12-20Genentech, Inc.$90Research paymentCash or cash equivalentHEMLIBRA Biological, HematologyAN OPEN LABEL STUDY TO DETERMINE PK AND PD OF HEMLIBRA IN SEVERE HEMOPHILIA A WITHOUT INHIBITORS2021
2021-12-17Travere Therapeutics, Inc.$1,120Research paymentCash or cash equivalent021FSGS160102021
2021-12-17Alexion Pharmaceuticals, Inc.$863Research paymentCash or cash equivalentAn Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP)2021
2021-12-17Alexion Pharmaceuticals, Inc.$863Research paymentCash or cash equivalentAn Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP)2021
2021-12-17Alexion Pharmaceuticals, Inc.$863Research paymentCash or cash equivalentAn Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP)2021
2021-12-17Alexion Pharmaceuticals, Inc.$863Research paymentCash or cash equivalentAn Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP)2021
2021-12-17Alexion Pharmaceuticals, Inc.$690Research paymentCash or cash equivalentAn Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP)2021
2021-12-16Edwards Lifesciences Corporation$6,630Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Early Feasibility (2016-04)2021
2021-12-16Edwards Lifesciences Corporation$2,000Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Early Feasibility (2016-04)2021
2021-12-16Edwards Lifesciences Corporation$1,530Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 2015-012021
2021-12-16Edwards Lifesciences Corporation$576Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Early Feasibility (2016-04)2021
2021-12-16Edwards Lifesciences Corporation$569Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 2015-012021
2021-12-16Edwards Lifesciences Corporation$568Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Early Feasibility (2016-04)2021
2021-12-13ABBVIE INC.$3,538Research paymentCash or cash equivalentLUPRON DEPOT Drug, ENDOCRINOLOGYA Phase 3, Multicenter, Open-Label, Two-Part Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynam2021
2021-12-13Gilead Sciences, Inc.$120Research paymentCash or cash equivalentSovaldi Drug, HCVA Long Term Follow-up Registry for Pediatric Subjects Who Received Treatment in Gilead-Sponsored Chronic Hepatitis C Inf2021
2021-12-10Luminex Corporation$1,200Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2021
2021-12-09Bio-Rad Laboratories, Inc.$7,109Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentDigital PCR Assays Device, PCR2021
2021-12-09Edwards Lifesciences Corporation$6,630Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Early Feasibility (2016-04)2021
2021-12-09Edwards Lifesciences Corporation$5,600Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2021
2021-12-09Edwards Lifesciences Corporation$5,460Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2021
2021-12-09Edwards Lifesciences Corporation$5,000Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2021
2021-12-09Edwards Lifesciences Corporation$4,590Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 2015-012021
2021-12-09Edwards Lifesciences Corporation$4,400Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Early Feasibility (2016-04)2021
2021-12-09Edwards Lifesciences Corporation$4,034Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Early Feasibility (2016-04)2021
2021-12-09Edwards Lifesciences Corporation$3,994Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2021
2021-12-09Edwards Lifesciences Corporation$3,640Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2021
2021-12-09Edwards Lifesciences Corporation$3,570Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 2015-012021
2021-12-09Edwards Lifesciences Corporation$3,060Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 2015-012021
2021-12-09Edwards Lifesciences Corporation$2,881Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Early Feasibility (2016-04)2021
2021-12-09Edwards Lifesciences Corporation$2,800Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2021
2021-12-09Edwards Lifesciences Corporation$2,550Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 2015-012021
2021-12-09Edwards Lifesciences Corporation$2,500Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2021
2021-12-09Edwards Lifesciences Corporation$2,275Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2021
2021-12-09Edwards Lifesciences Corporation$2,174Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2021
2021-12-09Edwards Lifesciences Corporation$2,000Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2021
2021-12-09Edwards Lifesciences Corporation$1,719Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2021
2021-12-09Edwards Lifesciences Corporation$1,530Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 2015-012021
2021-12-09Edwards Lifesciences Corporation$1,530Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Early Feasibility (2016-04)2021
2021-12-09Edwards Lifesciences Corporation$1,424Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 2015-012021
2021-12-09Edwards Lifesciences Corporation$1,422Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Early Feasibility (2016-04)2021
2021-12-09Edwards Lifesciences Corporation$1,235Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2021
2021-12-09Edwards Lifesciences Corporation$1,225Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 2015-012021
2021-12-09Edwards Lifesciences Corporation$1,225Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 2015-012021
2021-12-09Edwards Lifesciences Corporation$1,200Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Early Feasibility (2016-04)2021
2021-12-09Edwards Lifesciences Corporation$1,200Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2021
2021-12-09Edwards Lifesciences Corporation$854Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 2015-012021
2021-12-09Edwards Lifesciences Corporation$688Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2021
2021-12-09Edwards Lifesciences Corporation$569Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 2015-012021
2021-12-09Edwards Lifesciences Corporation$569Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 2015-012021
2021-12-09Edwards Lifesciences Corporation$354Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2021
2021-12-09Edwards Lifesciences Corporation$354Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2021
2021-12-09Edwards Lifesciences Corporation$284Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 2015-012021
2021-12-09Edwards Lifesciences Corporation$284Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Early Feasibility (2016-04)2021
2021-12-09Edwards Lifesciences Corporation$177Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2021
2021-12-09Edwards Lifesciences Corporation$88Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2021
2021-12-08PFIZER INC.$12,359Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2021
2021-12-08Merck Sharp & Dohme LLC$9,717Research paymentCash or cash equivalent Biological, VACCINEA Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerabilit2021
2021-12-08Incyte Corporation$42Research paymentCash or cash equivalentA Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr2021
2021-12-08Incyte Corporation$42Research paymentCash or cash equivalentA Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr2021
2021-12-08Incyte Corporation$24Research paymentCash or cash equivalentA Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr2021
2021-12-08Incyte Corporation$24Research paymentCash or cash equivalentA Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr2021
2021-12-08Incyte Corporation$24Research paymentCash or cash equivalentA Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr2021
2021-12-08Incyte Corporation$24Research paymentCash or cash equivalentA Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr2021
2021-12-08Incyte Corporation$20Research paymentCash or cash equivalentA Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr2021
2021-12-08Incyte Corporation$20Research paymentCash or cash equivalentA Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr2021
2021-12-07Organon Llc$81,596Research paymentCash or cash equivalentNEXPLANON Drug, CONTRACEPTIVESIntervention to Facilitate Contraception Provision by Pediatric Hospitalists: A Feasibility Study2021
2021-12-07Organon Llc$67,231Research paymentCash or cash equivalentNEXPLANON Drug, CONTRACEPTIVESImpact of basic training contraceptive education and access policy on contraceptive use and childbirth during the first 2021
2021-12-07BioFire Diagnostics, LLC$6,637Research paymentCash or cash equivalentFilmArray System Device, Clinical DiagnosticsFilmArray GI STA Pivotal Study2021
2021-12-07Dexcom, Inc.$5,127Research paymentCash or cash equivalentDEXCOM G6 TRANSMITTER Device, ENDOCRINOLOGYPOST APPROVAL STUDY FOR NON-ADJUNCTIVE USE OF DEXCOM G5 AND G6 CGM SYSTEM FOR DIABETES MANAGEMENT (COACH)2021
2021-12-07GLOBAL BLOOD THERAPEUTICS, INC.$1,545Research paymentCash or cash equivalentOXBRYTA Drug, SICKLE CELL DISEASEGBT_GBT440-038_3702_012021
2021-12-06Edwards Lifesciences Corporation$5,200Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Early Feasibility (2016-04)2021
2021-12-06Edwards Lifesciences Corporation$4,500Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Early Feasibility (2016-04)2021
2021-12-06Edwards Lifesciences Corporation$4,080Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Early Feasibility (2016-04)2021
2021-12-06Edwards Lifesciences Corporation$3,060Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Early Feasibility (2016-04)2021
2021-12-06Edwards Lifesciences Corporation$1,728Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Early Feasibility (2016-04)2021
2021-12-06Edwards Lifesciences Corporation$1,200Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Early Feasibility (2016-04)2021
2021-12-06Edwards Lifesciences Corporation$853Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Early Feasibility (2016-04)2021
2021-12-06Edwards Lifesciences Corporation$600Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Early Feasibility (2016-04)2021
2021-12-06Edwards Lifesciences Corporation$596Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Early Feasibility (2016-04)2021
2021-12-06Edwards Lifesciences Corporation$568Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Early Feasibility (2016-04)2021
2021-12-03Boehringer Ingelheim France S.A.S.$702Research paymentIn-kind items and servicesTRADJENTA Drug, DIABETES52 wks Eff. & Saf. Ph III in Paediatrics2021
2021-12-02PFIZER INC.$4,773Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2021
2021-12-01Novo Nordisk AS$601Research paymentCash or cash equivalentSogroya Biological, Growth HormoneNN8640-42632021
2021-12-01Travere Therapeutics, Inc.$35Research paymentCash or cash equivalent021IGAN170012021
2021-12-01Travere Therapeutics, Inc.$35Research paymentCash or cash equivalent021IGAN170012021
2021-12-01Boehringer Ingelheim Italia S.p.A.$13Research paymentIn-kind items and servicesOFEV Drug, RESPIRATORYPediatric ILD program2021
2021-11-29Organon Llc$81,596Research paymentCash or cash equivalentNEXPLANON Drug, CONTRACEPTIVESIntervention to Facilitate Contraception Provision by Pediatric Hospitalists: A Feasibility Study2021
2021-11-29Organon Llc$69,239Research paymentCash or cash equivalentNEXPLANON Drug, CONTRACEPTIVESA quasi-experimental, interrupted time series study to evaluate the effectiveness of "SexHealth Mobile" on uptake of con2021
2021-11-29Organon Llc$55,391Research paymentCash or cash equivalentNEXPLANON Drug, CONTRACEPTIVESA quasi-experimental, interrupted time series study to evaluate the effectiveness of "SexHealth Mobile" on uptake of con2021
2021-11-29BioFire Diagnostics, LLC$2,859Research paymentIn-kind items and servicesFilmArray Device, Clinical DiagnosticsEtiology and Prevalence of Acute Gastroenteritis (AGE) in US Children2021
2021-11-29Boehringer Ingelheim France S.A.S.$702Research paymentIn-kind items and servicesTRADJENTA Drug, DIABETES52 wks Eff. & Saf. Ph III in Paediatrics2021
2021-11-25PFIZER INC.$12,879Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2021
2021-11-17Travere Therapeutics, Inc.$1,229Research paymentCash or cash equivalent021FSGS160102021
2021-11-17Travere Therapeutics, Inc.$1,120Research paymentCash or cash equivalent021FSGS160102021
2021-11-15BioFire Diagnostics, LLC$5,290Research paymentCash or cash equivalentFilmArray System Device, Clinical DiagnosticsFilmArray GI STA Pivotal Study2021
2021-11-15Genentech, Inc.$90Research paymentCash or cash equivalentHEMLIBRA Biological, HematologyAN OPEN LABEL STUDY TO DETERMINE PK AND PD OF HEMLIBRA IN SEVERE HEMOPHILIA A WITHOUT INHIBITORS2021
2021-11-10PFIZER INC.$8,705Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2021
2021-11-10SANOFI PASTEUR INC.$450Research paymentCash or cash equivalentPSK0008 Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine (PCV) when Administered Concomitantly with Routine2021
2021-11-09BioFire Diagnostics, LLC$331Research paymentIn-kind items and servicesSpotFire RST Study2021
2021-11-07Genentech, Inc.$200Research paymentCash or cash equivalentHEMLIBRA Biological, HematologyAN OPEN LABEL STUDY TO DETERMINE PK AND PD OF HEMLIBRA IN SEVERE HEMOPHILIA A WITHOUT INHIBITORS2021
2021-11-07Genentech, Inc.$90Research paymentCash or cash equivalentHEMLIBRA Biological, HematologyAN OPEN LABEL STUDY TO DETERMINE PK AND PD OF HEMLIBRA IN SEVERE HEMOPHILIA A WITHOUT INHIBITORS2021
2021-11-05Genentech, Inc.$270Research paymentCash or cash equivalentHEMLIBRA Biological, HematologyAN OPEN LABEL STUDY TO DETERMINE PK AND PD OF HEMLIBRA IN SEVERE HEMOPHILIA A WITHOUT INHIBITORS2021
2021-11-03Genentech, Inc.$14,150Research paymentCash or cash equivalentHEMLIBRA Biological, HematologyAN OPEN LABEL STUDY TO DETERMINE PK AND PD OF HEMLIBRA IN SEVERE HEMOPHILIA A WITHOUT INHIBITORS2021
2021-11-03Allergan, Inc.$1,200Research paymentCash or cash equivalentDALVANCE Drug, ANTI-INFECTIVEA Phase 3, Multicenter, Open-Label, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin ve2021
2021-11-03Incyte Corporation$1,000Research paymentCash or cash equivalentA Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr2021
2021-11-03Astellas US Technologies$324Research paymentIn-kind items and servicesCRESEMBA Drug, HOSPITAL AND TRANSPLANTA Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco2021
2021-11-03Astellas US Technologies$324Research paymentIn-kind items and servicesCRESEMBA Drug, HOSPITAL AND TRANSPLANTA Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco2021
2021-11-03Astellas US Technologies$324Research paymentIn-kind items and servicesCRESEMBA Drug, HOSPITAL AND TRANSPLANTA Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco2021
2021-11-03Astellas US Technologies$324Research paymentIn-kind items and servicesCRESEMBA Drug, HOSPITAL AND TRANSPLANTA Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco2021
2021-11-03Astellas US Technologies$324Research paymentIn-kind items and servicesCRESEMBA Drug, HOSPITAL AND TRANSPLANTA Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco2021
2021-11-03Astellas US Technologies$324Research paymentIn-kind items and servicesCRESEMBA Drug, HOSPITAL AND TRANSPLANTA Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco2021
2021-11-03Astellas US Technologies$324Research paymentIn-kind items and servicesCRESEMBA Drug, HOSPITAL AND TRANSPLANTA Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco2021
2021-11-03Astellas US Technologies$324Research paymentIn-kind items and servicesCRESEMBA Drug, HOSPITAL AND TRANSPLANTA Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco2021
2021-11-03Astellas US Technologies$324Research paymentIn-kind items and servicesCRESEMBA Drug, HOSPITAL AND TRANSPLANTA Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco2021
2021-11-03Astellas US Technologies$324Research paymentIn-kind items and servicesCRESEMBA Drug, HOSPITAL AND TRANSPLANTA Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco2021
2021-11-03Astellas US Technologies$324Research paymentIn-kind items and servicesCRESEMBA Drug, HOSPITAL AND TRANSPLANTA Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco2021
2021-11-03Astellas US Technologies$324Research paymentIn-kind items and servicesCRESEMBA Drug, HOSPITAL AND TRANSPLANTA Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco2021
2021-11-03Astellas US Technologies$324Research paymentIn-kind items and servicesCRESEMBA Drug, HOSPITAL AND TRANSPLANTA Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco2021
2021-11-03Astellas US Technologies$324Research paymentIn-kind items and servicesCRESEMBA Drug, HOSPITAL AND TRANSPLANTA Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco2021
2021-11-03Astellas US Technologies$324Research paymentIn-kind items and servicesCRESEMBA Drug, HOSPITAL AND TRANSPLANTA Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco2021
2021-11-03Astellas US Technologies$324Research paymentIn-kind items and servicesCRESEMBA Drug, HOSPITAL AND TRANSPLANTA Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco2021
2021-11-03Astellas US Technologies$324Research paymentIn-kind items and servicesCRESEMBA Drug, HOSPITAL AND TRANSPLANTA Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco2021
2021-11-03Astellas US Technologies$324Research paymentIn-kind items and servicesCRESEMBA Drug, HOSPITAL AND TRANSPLANTA Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco2021
2021-11-03Astellas US Technologies$324Research paymentIn-kind items and servicesCRESEMBA Drug, HOSPITAL AND TRANSPLANTA Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco2021
2021-11-03Astellas US Technologies$324Research paymentIn-kind items and servicesCRESEMBA Drug, HOSPITAL AND TRANSPLANTA Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco2021
2021-11-03Astellas US Technologies$324Research paymentIn-kind items and servicesCRESEMBA Drug, HOSPITAL AND TRANSPLANTA Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco2021
2021-11-03Astellas US Technologies$324Research paymentIn-kind items and servicesCRESEMBA Drug, HOSPITAL AND TRANSPLANTA Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco2021
2021-11-03Astellas US Technologies$324Research paymentIn-kind items and servicesCRESEMBA Drug, HOSPITAL AND TRANSPLANTA Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco2021
2021-11-03Astellas US Technologies$324Research paymentIn-kind items and servicesCRESEMBA Drug, HOSPITAL AND TRANSPLANTA Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco2021
2021-11-03Astellas US Technologies$324Research paymentIn-kind items and servicesCRESEMBA Drug, HOSPITAL AND TRANSPLANTA Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco2021
2021-11-03Astellas US Technologies$324Research paymentIn-kind items and servicesCRESEMBA Drug, HOSPITAL AND TRANSPLANTA Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco2021
2021-11-01Alexion Pharmaceuticals, Inc.$863Research paymentCash or cash equivalentAn Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP)2021
2021-11-01Alexion Pharmaceuticals, Inc.$738Research paymentCash or cash equivalentAn Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP)2021
2021-11-01Alexion Pharmaceuticals, Inc.$235Research paymentCash or cash equivalentAn Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP)2021
2021-11-01Alexion Pharmaceuticals, Inc.$235Research paymentCash or cash equivalentAn Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP)2021
2021-11-01Alexion Pharmaceuticals, Inc.$235Research paymentCash or cash equivalentAn Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP)2021
2021-11-01Alexion Pharmaceuticals, Inc.$235Research paymentCash or cash equivalentAn Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP)2021
2021-11-01Alexion Pharmaceuticals, Inc.$235Research paymentCash or cash equivalentAn Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP)2021
2021-11-01Alexion Pharmaceuticals, Inc.$235Research paymentCash or cash equivalentAn Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP)2021
2021-11-01Alexion Pharmaceuticals, Inc.$235Research paymentCash or cash equivalentAn Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP)2021
2021-11-01Alexion Pharmaceuticals, Inc.$235Research paymentCash or cash equivalentAn Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP)2021
2021-11-01Alexion Pharmaceuticals, Inc.$235Research paymentCash or cash equivalentAn Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP)2021
2021-11-01Alexion Pharmaceuticals, Inc.$235Research paymentCash or cash equivalentAn Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP)2021
2021-11-01Travere Therapeutics, Inc.$35Research paymentCash or cash equivalent021IGAN170012021
2021-11-01Travere Therapeutics, Inc.$35Research paymentCash or cash equivalent021IGAN170012021
2021-11-01Boehringer Ingelheim Italia S.p.A.$13Research paymentIn-kind items and servicesOFEV Drug, RESPIRATORYPediatric ILD program2021
2021-10-29VERTEX PHARMACEUTICALS INCORPORATED$3,277Research paymentCash or cash equivalentA Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy i2021
2021-10-25ABBVIE INC.$700Research paymentCash or cash equivalentLUPRON DEPOT Drug, ENDOCRINOLOGYA Phase 3, Multicenter, Open-Label, Two-Part Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynam2021
2021-10-25Vero Biotech Inc.$184Food and BeverageCash or cash equivalentGenosyl Drug, Respiratory Therapy2021
2021-10-24Genentech, Inc.$2,000Research paymentCash or cash equivalentMircera Biological, HematologyCONFIRMATORY STUDY2021
2021-10-21PFIZER INC.$518Research paymentIn-kind items and servicesIBRANCE Drug, ONCOLOGYPHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PALBOCICLIB IBRANCEREGISTERED IN COMBINATION WITH IRINOTECA2021
2021-10-21PFIZER INC.$422Research paymentIn-kind items and servicesIBRANCE Drug, ONCOLOGYPHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PALBOCICLIB IBRANCEREGISTERED IN COMBINATION WITH IRINOTECA2021
2021-10-21PFIZER INC.$375Research paymentIn-kind items and servicesIBRANCE Drug, ONCOLOGYPHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PALBOCICLIB IBRANCEREGISTERED IN COMBINATION WITH IRINOTECA2021
2021-10-21PFIZER INC.$89Research paymentIn-kind items and servicesIBRANCE Drug, ONCOLOGYPHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PALBOCICLIB IBRANCEREGISTERED IN COMBINATION WITH IRINOTECA2021
2021-10-20Gilead Sciences, Inc.$2,312Research paymentCash or cash equivalentVemlidy Drug, HBVA Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala2021
2021-10-20Gilead Sciences, Inc.$633Research paymentCash or cash equivalentSovaldi Drug, HCVA Long Term Follow-up Registry for Pediatric Subjects Who Received Treatment in Gilead-Sponsored Chronic Hepatitis C Inf2021
2021-10-19Dexcom, Inc.$14,972Research paymentCash or cash equivalentDEXCOM G6 TRANSMITTER Device, ENDOCRINOLOGYPOST APPROVAL STUDY FOR NON-ADJUNCTIVE USE OF DEXCOM G5 AND G6 CGM SYSTEM FOR DIABETES MANAGEMENT (COACH)2021
2021-10-19PFIZER INC.$700Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2021
2021-10-18PFIZER INC.$3,296Research paymentIn-kind items and servicesIBRANCE Drug, ONCOLOGYPHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PALBOCICLIB IBRANCEREGISTERED IN COMBINATION WITH IRINOTECA2021
2021-10-18Travere Therapeutics, Inc.$2,556Research paymentCash or cash equivalentDUET2021
2021-10-18PFIZER INC.$1,068Research paymentIn-kind items and servicesIBRANCE Drug, ONCOLOGYPHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PALBOCICLIB IBRANCEREGISTERED IN COMBINATION WITH IRINOTECA2021
2021-10-18Travere Therapeutics, Inc.$1,000Research paymentCash or cash equivalentDUET2021
2021-10-14Aimmune Therapeutics, Inc.$133Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-10-13BioFire Diagnostics, LLC$4,681Research paymentIn-kind items and servicesFilmArray System Device, Clinical DiagnosticsFilmArray GI STA Pivotal Study2021
2021-10-06SANOFI PASTEUR INC.$1,955Research paymentCash or cash equivalentSTA00011 Stamaril Yellow Fever2021
2021-10-06GLOBAL BLOOD THERAPEUTICS, INC.$1,341Research paymentCash or cash equivalentOXBRYTA Drug, SICKLE CELL DISEASEGBT_GBT_PEDIATRIC_440-007_2926_012021
2021-10-01Alexion Pharmaceuticals, Inc.$60,000GrantCash or cash equivalent2021
2021-10-01BioFire Diagnostics, LLC$40,500Research paymentIn-kind items and servicesFilmArray System Device, Clinical DiagnosticsFilmArray GI STA Pivotal Study2021
2021-10-01VERTEX PHARMACEUTICALS INCORPORATED$5,010Research paymentCash or cash equivalentA Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy i2021
2021-10-01Boehringer Ingelheim Italia S.p.A.$13Research paymentIn-kind items and servicesOFEV Drug, RESPIRATORYPediatric ILD program2021
2021-09-30BioFire Diagnostics, LLC$3,431Research paymentIn-kind items and servicesFilmArray Device, Clinical DiagnosticsEtiology and Prevalence of Acute Gastroenteritis (AGE) in US Children2021
2021-09-30Boehringer Ingelheim Pharma GmbH & Co.KG$2,033Research paymentIn-kind items and servicesTRADJENTA Drug, DIABETES52 wks Eff. & Saf. Ph III in Paediatrics2021
2021-09-28PFIZER INC.$2,800Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2021
2021-09-23PFIZER INC.$11,200Research paymentCash or cash equivalentA RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAG2021
2021-09-22BioFire Diagnostics, LLC$8,412Research paymentCash or cash equivalentSpotFire RST Study2021
2021-09-22BioFire Diagnostics, LLC$5,174Research paymentCash or cash equivalentFilmArray System Device, Clinical DiagnosticsFilmArray GI STA Pivotal Study2021
2021-09-21PFIZER INC.$13,029Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2021
2021-09-20Regeneron Pharmaceuticals, Inc.$13,400Research paymentCash or cash equivalentEYLEA Biological, OPHTHALMOLOGYAn Extension Study to Evaluate the Long-Term Outcomes of Patients Who Received Treatment for Retinopathy of Prematurity 2021
2021-09-16PFIZER INC.$1,200Research paymentCash or cash equivalentA RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAG2021
2021-09-15United Therapeutics Corporation$2,100Research paymentCash or cash equivalentA SAFETY STUDY OF INTRAVENOUS INFUSION OF BONE MARROW MESENCHYMAL STEM CELL-DERIVED EXTRACELLULAR VESICLES (UNEX-42) IN 2021
2021-09-08PFIZER INC.$52,256Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2021
2021-09-08BioFire Diagnostics, LLC$300Research paymentIn-kind items and servicesSpotFire RST Study2021
2021-09-08BioFire Diagnostics, LLC$41Research paymentIn-kind items and servicesSpotFire RST Study2021
2021-09-07Aimmune Therapeutics, Inc.$175Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-09-07Aimmune Therapeutics, Inc.$175Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-09-07Aimmune Therapeutics, Inc.$115Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-09-03Luminex Corporation$7,980Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2021
2021-09-01JAZZ PHARMACEUTICALS INC.$133,381Research paymentIn-kind items and servicesVYXEOS Drug, HEMATOLOGY/ONCOLOGYA STUDY TO COMPARE STANDARD CHEMOTHERAPY TO THERAPY WITH CPX-351 AND/OR GILTERITINIB FOR PATIENTS WITH NEWLY DIAGNOSED A2021
2021-09-01Boehringer Ingelheim Italia S.p.A.$13Research paymentIn-kind items and servicesOFEV Drug, RESPIRATORYPediatric ILD program2021
2021-08-30Edwards Lifesciences Corporation$6,364Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 2015-012021
2021-08-30Edwards Lifesciences Corporation$3,324Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 2015-012021

The latest 200 records of 551.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Jackson CountyKansas City city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Kansas City, MO, county Jackson County, MO, state Missouri; placed by its city name.

MeasurePlace (city or town)
Kansas City, MO
County
Jackson County, MO
State
Missouri
Population B01003510,612719,9766,191,814
Population, 2020 census P1508,090717,2046,154,913
Median age B0100235.837.039.0
Under 18 B0100122.5%23.3%22.3%
65 and over B0100114.3%15.9%17.9%
Households B11001221,979306,7982,508,227
Foreign born B050028.6%6.6%4.5%
Median household income B19013$69,166$68,577$70,702
Median family income B19113$92,934$90,585$91,360
Per capita income B19301$41,393$39,559$39,695
Poverty rate B1700114.6%14.1%12.6%
Unemployment rate B230254.4%4.7%4.0%
Civilian labor force B23025279,828381,4333,120,639
Mean commute (minutes) B0801321.723.423.5
Bachelor's degree or higher B1500338.4%34.0%32.4%
Housing units B25001245,346336,2882,825,287
Owner-occupied B2500355.4%59.1%68.1%
Renters B2500344.6%40.9%31.9%
Median home value B25077$242,900$230,500$230,300
Median gross rent B25064$1,238$1,197$1,033
White, not Hispanic B0300254.0%59.3%76.3%
Black B0300225.2%22.0%10.9%
Hispanic or Latino B0300212.5%11.4%5.2%
Asian B030022.8%1.8%2.1%
American Indian and Alaska Native B030020.1%0.1%0.2%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Kansas City, MO.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.